Siwa Therapeutics
SIWA, a biotech firm, pioneers in developing therapies like SIWA 318H to slow/reverse aging by removing SCs.
Founded
2006SIWA, a biotech firm, pioneers in developing therapies like SIWA 318H to slow/reverse aging by removing SCs.
Founded in 2006, SIWA Therapeutics is a pre-clinical stage biotechnology company dedicated to developing biological therapies aimed at slowing or reversing the aging process. Their core mission is to enhance healthspan and lifespan by targeting and removing senescent cells (SCs), which are implicated in age-related dysfunction and degenerative diseases. The company's flagship product, SIWA 318H, is a proprietary humanized monoclonal antibody designed to eliminate these harmful cells, thereby improving overall cellular function.
SIWA Therapeutics has garnered attention for its innovative approach to combating aging and age-related diseases. The company has attracted notable investors and key figures in the biotech industry, although specific names are not disclosed. Their research and development efforts have led to significant advancements in understanding the role of SCs in aging, positioning SIWA as a promising player in the biotechnology sector. The impact of their work is poised to revolutionize treatments for age-related conditions, potentially extending healthy human lifespan.
Companies similar to Siwa Therapeutics include Siwa Biotech, Deciduous Therapeutics, Oisin Biotechnologies and HCW Biologics.
Siwa Therapeutics was founded in 2006.
Siwa Therapeutics' headquarters is located in Chicago, IL, US.
Siwa Therapeutics' most recent funding round was for $1.6M (USD) in May 2017.
As of May 22, 2017, Siwa Therapeutics has disclosed funding of $1.6M (USD). Undisclosed round amounts are excluded.
Siwa Therapeutics has 9 employees as of Feb 4, 2024.
HCW Biologics
hcwbiologics.com
